相关实验视频

Updated: Jul 24, 2026

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.6K

PTPRD突变是晚期非小细胞肺癌对ICI治疗敏感性的预后生物标志物

Zhixuan Ren1, Li Wang2, Chaohui Leng3

  • 1Department of Radiation Oncology, Huadong Hospital, Fudan University, Shanghai 200433, P.R. China.

Aging
|August 21, 2023
PubMed
概括

在接受免疫检查点抑制剂 (ICI) 治疗的高级非小细胞肺癌 (NSCLC) 患者中,PTPRD基因突变可能会预测更好的结果. 结合PTPRD突变的新型诺姆图可以改善接受ICI的NSCLC患者的生存预测.

关键词:
在NSCLCLC中,我们可以看到.这是PTPRD.在TCGA中,TCGA就是TCGA.免疫检查点抑制剂 免疫检查点抑制剂这个名字是名ogramogram.

更多相关视频

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.3K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.1K

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...